BiotechTube
Valora Therapeutics

Valora Therapeutics

San Francisco, United States· Est.
valoratherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $60M

Overview

Valora Therapeutics is a private, preclinical-stage biotech founded in 2023, based in San Francisco. It leverages Nobel-prize-winning glycobiology research from its scientific founder, Dr. Carolyn Bertozzi, to build its AbLec™ platform for discovering antibody-lectin fusion therapeutics. The company is backed by a syndicate of life science investors including Avalon BioVentures, Bregua Corporation, and Tiger Gene. Its mission is to translate insights into how sugars regulate immunity into transformative therapies for patients.

OncologyAutoimmune DiseasesInflammatory Diseases

Technology Platform

AbLec™ platform for creating antibody-lectin fusion proteins that target disease-specific glycan (sugar) patterns on cell surfaces to modulate immune responses.

Funding History

2
Total raised:$60M
Series A$45M
Seed$15M

Opportunities

The AbLec™ platform taps into the vast, underexplored therapeutic target space of the glycome, offering potential for highly specific drugs with novel mechanisms.
This could address limitations of current immunotherapies, creating opportunities in large markets like oncology and autoimmunity.
Strong foundational IP from Stanford and elite scientific backing provide a significant competitive moat.

Risk Factors

The platform is highly novel and unproven, carrying significant technical risk in developing safe, effective, and manufacturable glycan-targeting biologics.
As a pre-revenue, seed-stage company, Valora is dependent on raising future capital in a challenging funding environment.
Competition in the emerging field of therapeutic glycobiology is likely to intensify.

Competitive Landscape

Valora operates in the nascent but growing field of glycobiology-based therapeutics. Direct competitors are few but include other startups and academic spin-outs exploring lectin-based or glycan-targeting drugs. Indirectly, it competes with all established immunotherapy modalities (e.g., antibody drugs, cell therapies) for funding, talent, and ultimately, market share. Its exclusive license to foundational IP from a leading lab provides an early advantage.

More companies in Biologics / Biosimilars →More companies in United States →